Bristol-Myers Squibb Company (NYSE:BMY) ranks among the most active blue chip stocks to buy now. On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to Buy from Neutral, raising its price target to $65 from $46. Analyst Michael Yee noted a severely skewed risk/reward ratio to the potential in the latter half of 2026, with three to four key triggers that may propel the stock up as much as 25%.
Pixabay/Public Domain
The firm highlighted that Bristol-Myers Squibb Company will face loss of exclusivity challenges up to 2028, resulting in consensus reservations and a fairly low price-to-earnings ratio of 9x. Despite these obstacles, UBS estimates that the current stock price reflects the majority of the $20-30 billion LOE damage projected through 2028, albeit failing to account for future positive developments.
Bristol-Myers Squibb Company also showed recent findings at the American Society of Hematology Annual Meeting, highlighting updates on its lymphoma treatments, including the experimental drug golcadomide and the CAR T cell therapy Breyanz.
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, and manufactures innovative medicines to treat serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
